Drug Trial News

RSS
Idera reports $6.0 million net loss for fourth quarter 2010

Idera reports $6.0 million net loss for fourth quarter 2010

10 Mar 2011
Positive results from Creabilis CT327 Phase IIa study in patients with psoriasis vulgaris

Positive results from Creabilis CT327 Phase IIa study in patients with psoriasis vulgaris

10 Mar 2011
Santarus commences SAN-300 Phase I clinical study to treat inflammatory diseases

Santarus commences SAN-300 Phase I clinical study to treat inflammatory diseases

10 Mar 2011
CTI announces final pixantrone clinical trial design for treatment of DLBCL

CTI announces final pixantrone clinical trial design for treatment of DLBCL

10 Mar 2011
FDA accepts Tris' Extended Release Carbinoxamine Oral Suspension NDA for allergies in kids

FDA accepts Tris' Extended Release Carbinoxamine Oral Suspension NDA for allergies in kids

10 Mar 2011
Stemline's SL-401 receives FDA Orphan Drug designation for treatment of acute myeloid leukemia

Stemline's SL-401 receives FDA Orphan Drug designation for treatment of acute myeloid leukemia

10 Mar 2011
TARIS commences LiRIS Phase 1B clinical study in interstitial cystitis

TARIS commences LiRIS Phase 1B clinical study in interstitial cystitis

10 Mar 2011
NeuroDerm commences ND0611 Phase I/II trial to treat Parkinson's disease

NeuroDerm commences ND0611 Phase I/II trial to treat Parkinson's disease

9 Mar 2011
Auxilium completes patient enrollment in XIAFLEX phase III trial against Peyronie's disease

Auxilium completes patient enrollment in XIAFLEX phase III trial against Peyronie's disease

9 Mar 2011
ERYtech Pharma completes patient enrollment in GRASPA Phase II trial against ALL

ERYtech Pharma completes patient enrollment in GRASPA Phase II trial against ALL

9 Mar 2011
Vertex to present telaprevir and VX-222 study results against hepatitis C at EASL annual meeting

Vertex to present telaprevir and VX-222 study results against hepatitis C at EASL annual meeting

9 Mar 2011
Vermillion's CA125 positive preliminary data against ovarian tumors presented at WCSGO

Vermillion's CA125 positive preliminary data against ovarian tumors presented at WCSGO

9 Mar 2011
Wound Repair and Regeneration publishes positive findings from CXM's Matrix Phase 2b clinical study

Wound Repair and Regeneration publishes positive findings from CXM's Matrix Phase 2b clinical study

9 Mar 2011
Merck to present VICTRELIS phase III study data against HCV at EASL annual meeting

Merck to present VICTRELIS phase III study data against HCV at EASL annual meeting

9 Mar 2011
FDA approves Ipsen's application for Extended Dosing Interval of Somatuline Depot for acromegaly

FDA approves Ipsen's application for Extended Dosing Interval of Somatuline Depot for acromegaly

9 Mar 2011
FDA removes clinical hold for Amicus' AT2220 IND for treatment of Pompe disease

FDA removes clinical hold for Amicus' AT2220 IND for treatment of Pompe disease

9 Mar 2011
Unique gene therapy to combat Parkinson's disease

Unique gene therapy to combat Parkinson's disease

9 Mar 2011
Novartis QAB149 receives FDA Pulmonary-Allergy Advisory Committee approval for COPD

Novartis QAB149 receives FDA Pulmonary-Allergy Advisory Committee approval for COPD

9 Mar 2011
Treatment with sildenafil significantly reduces RP in patients with scleroderma

Treatment with sildenafil significantly reduces RP in patients with scleroderma

8 Mar 2011
Plexxikon commences PLX3397 Phase 2 trial in patients with Hodgkin lymphoma

Plexxikon commences PLX3397 Phase 2 trial in patients with Hodgkin lymphoma

8 Mar 2011

Terms

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

Provide Feedback